Intelligence Report · ~15 min read
Anesthesiology · Pediatric Surgery Therapeutic Area Assessment
12 signals · 3 insights · 37 regulatory precedents
Type
Therapeutic Area AssessmentGenerated
Jul 24, 2026
Confidence
Low Confidence · 59%
Evidence
52 items
Sources
2
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Therapeutic area assessment for Anesthesiology · Pediatric Surgery integrates 12 signals, 3 executive insights, and 37 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.
Key Developments
Material intelligence events ranked by strategic relevance.
- signalJul 2, 2026
Hologic Recalls BioZorb Markers Due to Patient Complications Risk
Hologic has recalled its BioZorb 3D bioabsorbable markers following reports of patient complications.
View detail - signalJul 20, 2026
Study on PVI Predictors in Laparoscopic Hysterectomy to Enhance Fluid Management
The study investigates predictors of Pleth Variability Index changes during laparoscopic hysterectomy, focusing on intraoperative positional shifts.
View detail - signalJul 16, 2026
Study on Perfusion Index vs Surgical Pleth Index for Pediatric Caudal Block Effectiveness
A study is underway to compare the Perfusion Index (PI) and Surgical Pleth Index (SPI) in assessing caudal block effectiveness in pediatric patients.
View detail - signalJul 14, 2026
Study on Minoxidil's Impact on Flap Viability in Breast Reconstruction
A clinical trial is assessing the effect of topical minoxidil on flap perfusion and viability in breast reconstruction surgeries.
View detail - regulatoryJul 20, 2026
Drug Trials Snapshots: PALSONIFY
PALSONIFY is a somatostatin receptor analog for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.
View detail - regulatoryJul 16, 2026
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
Application ANDA210456. Sponsor: APOTEX. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, TOCOPHEROL ACETATE, VITAMIN A, VITAMIN K.
View detail - regulatoryJul 16, 2026
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
Application ANDA210671. Sponsor: APOTEX. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, TOCOPHEROL ACETATE, VITAMIN A, VITAMIN K.
View detail - regulatoryJul 16, 2026
Pediatric Tracking Requirements Under FDAAA
Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as pediatric anesthesia practices.
View detail - insightJul 2, 2026
Hologic's BioZorb Recall Signals Regulatory and Market Challenges Ahead
The recall of Hologic's BioZorb markers due to patient complications poses significant risks to patient safety and regulatory compliance. This incident could lead to increased scrutiny from regulatory bodies and impact Hologic's market position and reputation in the surgical device sector. Regulatory context from FDA (Implantable Marker Recall: Hologic Removes BioZorb 3D Bioabsorbable Markers due to Risk for Patient Complications) supports the near-term read. Assessment grounded in 21 ranked evidence items (3 high-relevance).
View detail - insightJun 24, 2026
Impact of Bowel Preparation Trial on Infection Prevention Guidelines and Market Dynamics
This trial addresses a critical gap in surgical practices, potentially leading to significant changes in pre-surgical protocols for bowel preparation. The outcome could enhance patient comfort and reduce healthcare costs, making it a pivotal study for clinical strategy teams. Assessment grounded in 19 ranked evidence items (12 high-relevance).
View detail - insightJun 12, 2026
Impact of Midazolam Timing Study on Pediatric Anesthesia Practices
The ongoing clinical trial evaluating midazolam administration timing in pediatric adenotonsillectomy could reshape best practices in pediatric anesthesia. The results may lead to significant changes in clinical guidelines and impact the competitive landscape for anxiolytics in this therapeutic area. Regulatory context from FDA (FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)) supports the near-term read. Assessment grounded in 10 ranked evidence items (2 high-relevance).
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Executive insights surface 3 risk-calibrated assessments for portfolio review. 37 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 0 companies with active signal exposure for competitive and portfolio shifts.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
Drug Trials Snapshots: PALSONIFY
72%PALSONIFY is a somatostatin receptor analog for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.
Source: FDA
View evidenceFDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
83%Application ANDA210456. Sponsor: APOTEX. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, TOCOPHEROL ACETATE, VITAMIN A, VITAMIN K.
Source: FDA
View evidenceFDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
83%Application ANDA210671. Sponsor: APOTEX. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, TOCOPHEROL ACETATE, VITAMIN A, VITAMIN K.
Source: FDA
View evidencePediatric Tracking Requirements Under FDAAA
72%Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as pediatric anesthesia practices.
Source: FDA
View evidenceDemonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products
72%Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as pediatric anesthesia practices.
Source: FDA
View evidenceFDA AP — MALARONE PEDIATRIC (SUPPL)
72%Application NDA021078. Sponsor: GLAXOSMITHKLINE. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ATOVAQUONE, PROGUANIL HYDROCHLORIDE.
Source: FDA
View evidenceHologic's BioZorb Recall Signals Regulatory and Market Challenges Ahead
52%The recall of Hologic's BioZorb markers due to patient complications poses significant risks to patient safety and regulatory compliance. This incident could lead to increased scrutiny from regulatory bodies and impact Hologic's market position and reputation in the surgical device sector. Regulatory context from FDA (Implantable Marker Recall: Hologic Removes BioZorb 3D Bioabsorbable Markers due to Risk for Patient Complications) supports the near-term read. Assessment grounded in 21 ranked evidence items (3 high-relevance).
Source: Humanexa Insight
View evidenceImpact of Bowel Preparation Trial on Infection Prevention Guidelines and Market Dynamics
73%This trial addresses a critical gap in surgical practices, potentially leading to significant changes in pre-surgical protocols for bowel preparation. The outcome could enhance patient comfort and reduce healthcare costs, making it a pivotal study for clinical strategy teams. Assessment grounded in 19 ranked evidence items (12 high-relevance).
Source: Humanexa Insight
View evidenceImpact of Midazolam Timing Study on Pediatric Anesthesia Practices
51%The ongoing clinical trial evaluating midazolam administration timing in pediatric adenotonsillectomy could reshape best practices in pediatric anesthesia. The results may lead to significant changes in clinical guidelines and impact the competitive landscape for anxiolytics in this therapeutic area. Regulatory context from FDA (FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)) supports the near-term read. Assessment grounded in 10 ranked evidence items (2 high-relevance).
Source: Humanexa Insight
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- Hologic Recalls BioZorb Markers Due to Patient Complications Risk
Safety Signal
- Study on PVI Predictors in Laparoscopic Hysterectomy to Enhance Fluid Management
Trial Update
- Study on Perfusion Index vs Surgical Pleth Index for Pediatric Caudal Block Effectiveness
Trial Update
- Study on Minoxidil's Impact on Flap Viability in Breast Reconstruction
Trial Update
- Wrist-Ankle Acupuncture Shows Promise for Preventing Postoperative Nausea in High-Risk Patients
Trial Update
- Study on Intraoperative Chest Tube Removal in Thoracoscopic Wedge Resection
Trial Update
- Study Compares vNOTES and Laparoscopy on Respiratory and Hemodynamic Outcomes
Trial Update
- Trial Protocol for Liposomal Bupivacaine in Shoulder Arthroscopy Pain Management
Trial Update
Insights
- Hologic's BioZorb Recall Signals Regulatory and Market Challenges Ahead
Surgery · Medical Devices
- Impact of Bowel Preparation Trial on Infection Prevention Guidelines and Market Dynamics
Surgery · Infection Prevention
- Impact of Midazolam Timing Study on Pediatric Anesthesia Practices
Anesthesiology · Pediatric Surgery